News: Portfolio 2005

VENTAIRA PHARMACEUTICALS ANNOUNCES $13.5M PRIVATE EQUITY FINANCING

(continued)

 

"We are very pleased with the progress Ventaira has enjoyed over the past 9 months and closing on this round of financing validates our confidence in the Company," said Morton Collins, Chairman of the Board. "This investment positions Ventaira to build significant value and address challenging medical needs in our society."

 

About Ventaira Pharmaceuticals

Ventaira Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development of new inhalation products by utilizing its novel proprietary electrohydrodynamic (EHD) aerosolization and formulation technologies. For more information, please visitwww.ventaira.com.

 

About TL Ventures

TL Ventures (www.tlventures.com), established in 1988, has over $1.4 billion under management and is currently making new investments from its sixth fund, TL Ventures V, which has $686 million in committed capital. Focused on venture investing in category-defining, early-stage companies in information technology, communications and biotechnology, the Firm provides portfolio companies with operational, entrepreneurial and financial expertise and a global network of resources and contacts. TL Ventures has offices in Philadelphia, Austin and Silicon Valley.

 

About Battelle Ventures

Established in August 2003, Battelle Ventures, L.P., a $150m venture fund, principally, but not exclusively, focuses on seed, start-up and first-stage investments that will commercialize the technologies that emerge from Battelle Memorial Institute and the National Laboratories that Battelle manages or co-manages for the U.S. Department of Energy. For more information, please visit www.battelleventures.com.

Page: 1 2 3 4 5